Head to head
Pemvidutide against Semaglutide
Pemvidutide is developed with an explicit claim about the composition of the weight lost rather than the amount. That claim is about lean mass, which is measured by scan and not by any outcome, and it has not been tested against semaglutide in a randomised trial.
Column A
PemvidutidePemvidutide (GLP-1 / glucagon dual agonist)
Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Pemvidutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 PERFORMA in MASH started August 2026; FDA Breakthrough Therapy designation for MASH) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | Supports weekly dosing | ~7 days |
| Molecular weight | 3,873.4 Da | 4,113.6 Da |
| Mechanism | Agonizes GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure and reduced liver fat. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 3 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Pemvidutide and Semaglutide?
Pemvidutide: Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Pemvidutide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Pemvidutide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Pemvidutide and Semaglutide FDA-approved?
Pemvidutide: Investigational (Phase 3 PERFORMA in MASH started August 2026; FDA Breakthrough Therapy designation for MASH). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Pemvidutide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.